-
A Learning Program for Treatment Recommendations by Molecular Tumor Boards and Artificial Intelligence. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-30 Kuniko Sunami,Yoichi Naito,Yusuke Saigusa,Toraji Amano,Daisuke Ennishi,Mitsuho Imai,Hidenori Kage,Masashi Kanai,Hirotsugu Kenmotsu,Keigo Komine,Takafumi Koyama,Takahiro Maeda,Sachi Morita,Daisuke Sakai,Makoto Hirata,Mamoru Ito,Toshiyuki Kozuki,Hiroyuki Sakashita,Hidehito Horinouchi,Yusuke Okuma,Atsuo Takashima,Toshio Kubo,Shuichi Hironaka,Yoshihiko Segawa,Yoshihiro Yakushijin,Hideaki Bando,Akitaka
Importance Substantial heterogeneity exists in treatment recommendations across molecular tumor boards (MTBs), especially for biomarkers with low evidence levels; therefore, the learning program is essential. Objective To determine whether a learning program sharing treatment recommendations for biomarkers with low evidence levels contributes to the standardization of MTBs and to investigate the efficacy
-
Structural Racism and Lung Cancer Risk: A Scoping Review. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-30 Sidra N Bonner,Richard Curley,Kyra Love,Tola Akande,Aamna Akhtar,Loretta Erhunmwunsee
Importance Structural racism is associated with persistent inequities in health and health outcomes in the US for racial and ethnic minority groups. This review summarizes how structural racism contributes to differential population-level exposure to lung cancer risk factors and thus disparate lung cancer risk across different racial and ethnic groups. Observations A scoping review was conducted focusing
-
Contemporary Trends in Reviewing Test Results Through the Electronic Patient Portal Among Patients With Cancer. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-30 Sheena Bhalla,Tanushree Prasad,Donglu Xie,David E Gerber
-
Expanding Access to High-Quality Cancer Care Through Policy-California Cancer Care Equity Act. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Adrian Diaz,Andrew Loehrer,Timothy M Pawlik
-
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Priyanka Sharma,Shane R Stecklein,Rachel Yoder,Joshua M Staley,Kelsey Schwensen,Anne O'Dea,Lauren Nye,Deepti Satelli,Gregory Crane,Rashna Madan,Maura F O'Neil,Jamie Wagner,Kelsey E Larson,Christa Balanoff,Lyndsey Kilgore,Milind A Phadnis,Andrew K Godwin,Roberto Salgado,Qamar J Khan,Joyce O'Shaughnessy
Importance Addition of pembrolizumab to anthracycline-based chemotherapy improves pathologic complete response (pCR) and event-free survival (EFS) in triple-negative breast cancer (TNBC). The efficacy of anthracycline-free chemoimmunotherapy in TNBC has not been assessed. Objective To assess the efficacy of the anthracycline-free neoadjuvant regimen of carboplatin and docetaxel plus pembrolizumab in
-
Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns? JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Victoria E Wang,Justin F Gainor
-
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Layla Parast,Lu Tian,Lee-Jen Wei
-
Mortality and Hospitalization Risks in Patients With Cancer and the SARS-CoV-2 Omicron Variant. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Jonathan Ofer,Genady Drozdinsky,Bar Basharim,Adi Turjeman,Noa Eliakim-Raz,Salomon M Stemmer
-
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Oliver Klein
-
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-22 Yusuke Okuma,Kaoru Kubota,Mototsugu Shimokawa,Kana Hashimoto,Yosuke Kawashima,Tomohiro Sakamoto,Hiroshi Wakui,Shuji Murakami,Kyoichi Okishio,Kenji Hayashihara,Yuichiro Ohe,
Importance Non-small cell lung cancer (NSCLC) with uncommon EGFR mutations is a rare subgroup, composing 14% of all EGFR mutations. Objective To determine the usefulness of osimertinib in previously untreated patients with metastatic NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion mutations. Design, Setting, and Participants This multicenter, open-label, single-group, phase 2 nonrandomized
-
Distribution of Cancer Care Resources Across US Hospitals by Patient Race and Ethnicity. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-16 Gracie Himmelstein,Patricia A Ganz
-
Immunotherapy in Prepatients-Preventing or Promoting a Malignant Transformation? JAMA Oncol. (IF 28.4) Pub Date : 2023-11-16 Bishal Gyawali,Garth W Strohbehn
-
Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-16 Glenn J Hanna,Alessandro Villa,Shuvro P Nandi,Ruichao Shi,Anne ONeill,Mofei Liu,Charles T Quinn,Nathaniel S Treister,Herve Y Sroussi,Piamkamon Vacharotayangul,Laura A Goguen,Donald J Annino,Eleni M Rettig,Vickie Y Jo,Kristine S Wong,Patrick Lizotte,Cloud P Paweletz,Ravindra Uppaluri,Robert I Haddad,Ezra E W Cohen,Ludmil B Alexandrov,William N William,Scott M Lippman,Sook-Bin Woo
Importance Proliferative verrucous leukoplakia (PVL) is an aggressive oral precancerous disease characterized by a high risk of transformation to invasive oral squamous cell carcinoma (OSCC), and no therapies have been shown to affect its natural history. A recent study of the PVL immune landscape revealed a cytotoxic T-cell-rich microenvironment, providing strong rationale to investigate immune checkpoint
-
Cost Savings and Waste Reduction Through Redispensing Unused Oral Anticancer Drugs: The ROAD Study. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-16 Elisabeth M Smale,Bart J F van den Bemt,Eibert R Heerdink,Ingrid M E Desar,Toine C G Egberts,Charlotte L Bekker,
Importance New strategies targeting waste are required to improve financial and ecologic sustainability of expensive therapies, such as oral anticancer drugs, that frequently remain unused by patients. Redispensing unused oral anticancer drugs seems to be a promising strategy when drug quality is guaranteed. Objectives To determine the waste reduction and net cost savings attained by redispensing oral
-
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-16 Dipesh Uprety,Howard Jack West
-
Moving Toward Personalized Colorectal Cancer Follow-Up Care. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-16 Dong Hang,Markus Dines Knudsen,Mingyang Song
-
Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-16 Jesper Nors,Lene Hjerrild Iversen,Rune Erichsen,Kåre Andersson Gotschalck,Claus Lindbjerg Andersen
Importance Management of colorectal cancer (CRC) has been updated continuously over the past 2 decades. While the combination of these initiatives has had implications for improved survival, the implications for rates of recurrence remain unexplored. Objective To ascertain the rates of recurrence and describe time to recurrence within 5 years of surgery with curative intent for stages I to III CRC
-
Practice Patterns for Organ Preservation in US Patients With Rectal Cancer, 2006-2020. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-09 Anthony Loria,Mohamedtaki A Tejani,Larissa K Temple,Carla F Justiniano,Alexa D Melucci,Adan Z Becerra,John R T Monson,Christopher T Aquina,Fergal J Fleming
Importance In March 2023, the National Comprehensive Cancer Network endorsed watch and wait for those with complete clinical response to total neoadjuvant therapy. Neoadjuvant therapy is highly efficacious, so this recommendation may have broad implications, but the current trends in organ preservation in the US are unknown. Objective To describe organ preservation trends among patients with rectal
-
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy: A Review. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-09 Marco Ventin,Giulia Cattaneo,Luke Maggs,Shahrzad Arya,Xinhui Wang,Cristina R Ferrone
Importance Chimeric antigen receptor (CAR) T-cell therapy has redefined the therapeutic landscape of several hematologic malignant tumors. Despite its clinical efficacy, many patients with cancer experience nonresponse to CAR T-cell treatment, disease relapse within months, or severe adverse events. Furthermore, CAR T-cell therapy has demonstrated minimal to no clinical efficacy in the treatment of
-
Outcomes in Patients With Postchemotherapy Residual Nonretroperitoneal Disease in Nonseminomatous Germ Cell Tumors. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-09 Jennifer King,Ryan Ashkar,Kenneth Kesler,Sandra K Althouse,Nasser H Hanna,Lawrence H Einhorn,Nabil Adra
-
Bacterial Decolonization for Prevention of Radiation Dermatitis-Fragility Index Analysis. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-09 Shubhangi Shah,Ronald Chow,Charles B Simone
-
Global Stage Distribution of Breast Cancer at Diagnosis: A Systematic Review and Meta-Analysis. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-09 Javier David Benitez Fuentes,Eileen Morgan,Alicia de Luna Aguilar,Allini Mafra,Richa Shah,Francesco Giusti,Jérôme Vignat,Ariana Znaor,Carina Musetti,Cheng-Har Yip,Liesbet Van Eycken,Elima Jedy-Agba,Marion Piñeros,Isabelle Soerjomataram
Importance Stage at diagnosis is a key prognostic factor for cancer survival. Objective To assess the global distribution of breast cancer stage by country, age group, calendar period, and socioeconomic status using population-based data. Data Sources A systematic search of MEDLINE and Web of Science databases and registry websites and gray literature was conducted for articles or reports published
-
Assessment of Changes in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-09 Leticia M Nogueira,Elizabeth J Schafer,Qinjin Fan,Nikita Sandeep Wagle,Jingxuan Zhao,Kewei Sylvia Shi,Xuesong Han,Ahmedin Jemal,K Robin Yabroff
Importance The COVID-19 pandemic led to disruptions in access to health care, including cancer care. The extent of changes in receipt of cancer treatment is unclear. Objective To evaluate changes in the absolute number, proportion, and cancer treatment modalities provided to patients with newly diagnosed cancer during 2020, the first year of the pandemic. Design, Setting, and Participants In this cohort
-
Diagnostic Outcomes of Concurrent DNA and RNA Sequencing in Individuals Undergoing Hereditary Cancer Testing. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-04 Carolyn Horton,Lily Hoang,Heather Zimmermann,Colin Young,Jessica Grzybowski,Kate Durda,Huy Vuong,David Burks,Ashley Cass,Holly LaDuca,Marcy E Richardson,Steven Harrison,Elizabeth C Chao,Rachid Karam
Importance Personalized surveillance, prophylaxis, and cancer treatment options for individuals with hereditary cancer predisposition are informed by results of germline genetic testing. Improvements to genomic technology, such as the availability of RNA sequencing, may increase identification of individuals eligible for personalized interventions by improving the accuracy and yield of germline testing
-
Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-02 Lauren McVicker,Alexander M Labeit,Carol A C Coupland,Blánaid Hicks,Carmel Hughes,Úna McMenamin,Stuart A McIntosh,Peter Murchie,Chris R Cardwell
Importance Genitourinary syndrome of menopause can be treated with vaginal estrogen therapy. However, there are concerns about the safety of vaginal estrogen therapy in patients with breast cancer. Objective To determine whether the risk of breast cancer-specific mortality was higher in females with breast cancer who used vaginal estrogen therapy vs females with breast cancer who did not use hormone
-
Breast Cancer Incidence After a False-Positive Mammography Result. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-02 Xinhe Mao,Wei He,Keith Humphreys,Mikael Eriksson,Natalie Holowko,Haomin Yang,José Tapia,Per Hall,Kamila Czene
Importance False-positive mammography results are common. However, long-term outcomes after a false-positive result remain unclear. Objectives To examine long-term outcomes after a false-positive mammography result and to investigate whether the association of a false-positive mammography result with cancer differs by baseline characteristics, tumor characteristics, and time since the false-positive
-
Exclusion of Ranitidine From Premedication Regimens During Paclitaxel Treatment. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-02 Daan W Huntjens,Joost W Vanhommerig,Willem van de Veen,Mirjam Crul
-
Ending One's Life Is Not Always a Sign of Psychopathology-Reply. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Alexandra L Potter,Chinmay Haridas,Chi-Fu Jeffrey Yang
-
Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Stuart J Wong,Pedro A Torres-Saavedra,Nabil F Saba,George Shenouda,Jeffrey M Bumpous,Robert E Wallace,Christine H Chung,Adel K El-Naggar,Clement K Gwede,Barbara Burtness,Paul A Tennant,Neal E Dunlap,Rebecca Redman,William A Stokes,Soumon Rudra,Loren K Mell,Assuntina G Sacco,Sharon A Spencer,Lisle Nabell,Min Yao,Fabio L Cury,Darrion L Mitchell,Christopher U Jones,Selim Firat,Joseph N Contessa,Thomas
Importance Patients with locally advanced non-human papillomavirus (HPV) head and neck cancer (HNC) carry an unfavorable prognosis. Chemoradiotherapy (CRT) with cisplatin or anti-epidermal growth factor receptor (EGFR) antibody improves overall survival (OS) of patients with stage III to IV HNC, and preclinical data suggest that a small-molecule tyrosine kinase inhibitor dual EGFR and ERBB2 (formerly
-
Geriatric Assessments in Older Adults With Cancer. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Fernando C Diaz,Ana I Velazquez,Mazie Tsang
-
Unlocking the Potential of Anti-TIGIT Therapy-Between Promise and Challenges. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Joud Hajjar,Mohamed H Derbala,Aung Naing
-
Climate Change and Cancer Care-Feeling the Heat. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Joan H Schiller,Eric Bernicker,Alexandra Thomas
-
Ending One's Life Is Not Always a Sign of Psychopathology. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Douglas W Heinrichs
-
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Tae Won Kim,Philippe L Bedard,Patricia LoRusso,Michael S Gordon,Johanna Bendell,Do-Youn Oh,Myung-Ju Ahn,Elena Garralda,Sandra P D'Angelo,Jayesh Desai,F Stephen Hodi,Zev Wainberg,Jean-Pierre Delord,Phillippe A Cassier,Andrés Cervantes,Marta Gil-Martin,Benjamin Wu,Namrata S Patil,Yanling Jin,Tien Hoang,Diana Mendus,Xiaohui Wen,Raymond Meng,Byoung Chul Cho
Importance Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab in programmed death ligand 1-selected tumors. Objective To evaluate the safety and antitumor activity of the anti-TIGIT antibody tiragolumab and its combination with atezolizumab in patients with advanced solid tumors. Design, Setting
-
Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Oreste Davide Gentilini,Edoardo Botteri,Claudia Sangalli,Viviana Galimberti,Mauro Porpiglia,Roberto Agresti,Alberto Luini,Giuseppe Viale,Enrico Cassano,Nickolas Peradze,Antonio Toesca,Giulia Massari,Virgilio Sacchini,Elisabetta Munzone,Maria Cristina Leonardi,Francesca Cattadori,Rosa Di Micco,Emanuela Esposito,Adele Sgarella,Silvia Cattaneo,Massimo Busani,Massimo Dessena,Anna Bianchi,Elisabetta Cretella
Importance Sentinel lymph node biopsy (SLNB) is the standard of care for axillary node staging of patients with early breast cancer (BC), but its necessity can be questioned since surgery for examination of axillary nodes is not performed with curative intent. Objective To determine whether the omission of axillary surgery is noninferior to SLNB in patients with small BC and a negative result on preoperative
-
Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Burcu F Darst,Ed Saunders,Tokhir Dadaev,Xin Sheng,Peggy Wan,Loreall Pooler,Lucy Y Xia,Stephen Chanock,Sonja I Berndt,Ying Wang,Alpa V Patel,Demetrius Albanes,Stephanie J Weinstein,Vincent Gnanapragasam,Chad Huff,Fergus J Couch,Alicja Wolk,Graham G Giles,Tu Nguyen-Dumont,Roger L Milne,Mark M Pomerantz,Julie A Schmidt,Ruth C Travis,Timothy J Key,Konrad H Stopsack,Lorelei A Mucci,William J Catalona,Beth
Importance Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease. Objective To identify genes associated with aggressive PCa. Design, Setting, and Participants
-
Sentinel Node Biopsy for Early Breast Cancer-A SOUND for De-escalation. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Seema A Khan
-
Medical Travel for Immigrant Patients With Cancer-Returning Home. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Nishwant Swami,Edward Christopher Dee,Narjust Florez
-
Risk of Death Due to Pregnancy-Associated Cancers-More Questions Than Answers-Reply. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Zoe F Cairncross,Gregg Nelson,Amy Metcalfe
-
Primary Thromboprophylaxis in People With Cancer-Where Next? JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Alok A Khorana
-
Rare Genetic Drivers of Lethal Prostate Cancer. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Alexander W Wyatt
-
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Marliese Alexander,Sam Harris,Craig Underhill,Javier Torres,Sharad Sharma,Nora Lee,HuiLi Wong,Richard Eek,Michael Michael,Jeanne Tie,Jennifer Rogers,Alexander G Heriot,David Ball,Michael MacManus,Rory Wolfe,Benjamin J Solomon,Kate Burbury
Importance Thromboprophylaxis for individuals receiving systemic anticancer therapies has proven to be effective. Potential to maximize benefits relies on improved risk-directed strategies, but existing risk models underperform in cohorts with lung and gastrointestinal cancers. Objective To assess clinical benefits and safety of biomarker-driven thromboprophylaxis and to externally validate a biomarker
-
Risk of Death Due to Pregnancy-Associated Cancers-More Questions Than Answers. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Jordyn Silverstein,Katherine Van Loon
-
The Weight of Inevitability-My Journey With BRCA2. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Katherine P Wu
-
Right-Sizing Models of Genetic Cancer Predisposition Testing. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Huma Q Rana,Judy E Garber
-
Prevalence of Thromboembolic Events in Patients With Non-Small Cell Lung Cancer and RET Fusions. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Mihaela Aldea,Arianna Marinello,David Guyon,Anas Gazzah,Fabrice Barlesi,David Planchard,Benjamin Besse
-
Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Michael F Gensheimer,Harriet Gee,Hiroki Shirato,Hiroshi Taguchi,John M Snyder,Alexander L Chin,Lucas K Vitzthum,Peter G Maxim,Heather A Wakelee,Joel Neal,Millie Das,Daniel T Chang,Elizabeth Kidd,Steven L Hancock,David B Shultz,Kathleen C Horst,Quynh-Thu Le,Samantha Wong,Eleanor Brown,Ngan Nguyen,Rachel Liang,Billy W Loo,Maximilian Diehn
Importance Stereotactic ablative radiotherapy (SABR) is used for treating lung tumors but can cause toxic effects, including life-threatening damage to central structures. Retrospective data suggested that small tumors up to 10 cm3 in volume can be well controlled with a biologically effective dose less than 100 Gy. Objective To assess whether individualizing lung SABR dose and fractionation by tumor
-
Remotely Delivered Cancer Genetic Testing in the Making Genetic Testing Accessible (MAGENTA) Trial: A Randomized Clinical Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Elizabeth M Swisher,Nadine Rayes,Deborah Bowen,Christine B Peterson,Barbara M Norquist,Tara Coffin,Kathleen Gavin,Deborah Polinsky,Jamie Crase,Jamie N Bakkum-Gamez,Stephanie V Blank,Mark F Munsell,Denise Nebgen,Gini F Fleming,Olufunmilayo I Olopade,Sherman Law,Alicia Zhou,Douglas A Levine,Alan D'Andrea,Karen H Lu
Importance Requiring personalized genetic counseling may introduce barriers to cancer risk assessment, but it is unknown whether omitting counseling could increase distress. Objective To assess whether omitting pretest and/or posttest genetic counseling would increase distress during remote testing. Design, Setting, and Participants Making Genetic Testing Accessible (MAGENTA) was a 4-arm, randomized
-
Personalized Radiation Therapy-Spurning the "One Size Fits All" Approach. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Vivek Verma
-
Advancing Patient-Centered Outcomes and Equity in Clinical Trials for BCG-Unresponsive Nonmuscle Invasive Bladder Cancer. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Thomas J Hwang,Benjamin J Davies,Mark A Preston
-
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Manuel David Gil-Sierra,María Del Pilar Briceño-Casado,Cristina Moreno-Ramos
-
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen-Reply. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Gaia Giannone,Iain A McNeish,Susana Banerjee
-
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Motoko Tachihara,Kayoko Tsujino,Takeaki Ishihara,Hidetoshi Hayashi,Yuki Sato,Takayasu Kurata,Shunichi Sugawara,Yoshimasa Shiraishi,Shunsuke Teraoka,Koichi Azuma,Haruko Daga,Masafumi Yamaguchi,Takeshi Kodaira,Miyako Satouchi,Mototsugu Shimokawa,Nobuyuki Yamamoto,Kazuhiko Nakagawa,
Importance Administration of durvalumab after concurrent chemoradiotherapy is the standard treatment of unresectable, locally advanced non-small cell lung cancer (NSCLC); however, 20% to 30% of patients do not receive durvalumab because of adverse events (AEs) during concurrent chemoradiotherapy. In addition, radiotherapy and immunotherapy have a synergistic effect. Objective To investigate the efficacy
-
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs? JAMA Oncol. (IF 28.4) Pub Date : 2023-11-01 Austin Wesevich,Mark J Ratain
-
Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs. JAMA Oncol. (IF 28.4) Pub Date : 2023-10-26 Lecia V Sequist,Erica T Warner,Chi-Fu Jeffrey Yang
-
Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases. JAMA Oncol. (IF 28.4) Pub Date : 2023-10-26 Emily S Lebow,Luke R G Pike,Andrew D Seidman,Nelson Moss,Kathryn Beal,Yao Yu
-
Expanding Treatment Options for Older Adults With Prostate Cancer. JAMA Oncol. (IF 28.4) Pub Date : 2023-10-26 Alicia Morgans
-
-
Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US. JAMA Oncol. (IF 28.4) Pub Date : 2023-10-26 Eunji Choi,Victoria Y Ding,Sophia J Luo,Kevin Ten Haaf,Julie T Wu,Jacqueline V Aredo,Lynne R Wilkens,Neal D Freedman,Leah M Backhus,Ann N Leung,Rafael Meza,Natalie S Lui,Christopher A Haiman,Sung-Shim Lani Park,Loïc Le Marchand,Joel W Neal,Iona Cheng,Heather A Wakelee,Martin C Tammemägi,Summer S Han
Importance The revised 2021 US Preventive Services Task Force (USPSTF) guidelines for lung cancer screening have been shown to reduce disparities in screening eligibility and performance between African American and White individuals vs the 2013 guidelines. However, potential disparities across other racial and ethnic groups in the US remain unknown. Risk model-based screening may reduce racial and
-
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial. JAMA Oncol. (IF 28.4) Pub Date : 2023-10-26 Andreas Peyrl,Monika Chocholous,Magnus Sabel,Alvaro Lassaletta,Jaroslav Sterba,Pierre Leblond,Karsten Nysom,Ingrid Torsvik,Susan N Chi,Thomas Perwein,Neil Jones,Stefan Holm,Per Nyman,Helena Mörse,Anders Öberg,Liesa Weiler-Wichtl,Ulrike Leiss,Christine Haberler,Maresa T Schmook,Lisa Mayr,Karin Dieckmann,Marcel Kool,Johannes Gojo,Amedeo A Azizi,Nicolas André,Mark Kieran,Irene Slavc
Importance Medulloblastoma recurrence in patients who have previously received irradiation has a dismal prognosis and lacks a standard salvage regimen. Objective To evaluate the response rate of pediatric patients with medulloblastoma recurrence using an antiangiogenic metronomic combinatorial approach (Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial [MEMMAT]). Design, Setting